Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00772577 · ClinicalTrials.gov registry record · Phase 4
Study of the Efficacy and Safety of Aliskiren HCTZ vs Ramipril in Obese Patients (BMI ≥ 30) With Stage 2 Hypertension
A Phase 4 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 4
- Development phase
- 386
- Enrollment target
NCT00772577 is a Phase 4 study that has completed, run by Novartis. The registered enrollment target is 386 participants.
The verdict
NCT00772577, a Phase 4 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 386 participants
- Enrollment target
Study Summary
Study to Evaluate the Efficacy and Safety of Aliskiren Hydrochlorothiazide (HCTZ) vs Ramipril in Obese patients (BMI ≥ 30) with Stage 2 Hypertension
Interventions
- DRUG Ramipril
- DRUG Aliskiren Hydrochlorothiazide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 386 participants |
| Start Date | 2008-08 |
| Est. Completion | 2009-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00772577
The ClinicalTrials.gov registry entry for NCT00772577 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 386 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ramipril is the first listed.
NCT00772577 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00772577 about?
NCT00772577 is a clinical study titled "Study of the Efficacy and Safety of Aliskiren HCTZ vs Ramipril in Obese Patients (BMI ≥ 30) With Stage 2 Hypertension". Study to Evaluate the Efficacy and Safety of Aliskiren Hydrochlorothiazide (HCTZ) vs Ramipril in Obese patients (BMI ≥ 30) with Stage 2 Hypertension
What is the current status of trial NCT00772577?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 386 participants. The study started on 2008-08. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00772577?
The interventions under investigation include: Ramipril (DRUG), Aliskiren Hydrochlorothiazide (DRUG).
Who is sponsoring clinical trial NCT00772577?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.